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Case Report
Eosinophilic Pneumonia in a Patient with 
Ulcerative Colitis 
Keyur B. Patel, M.D., Matthew M. Robbins, M.D., Mitchell L. Simon, M.D., and 
Judith K. Amorosa, M.D.
We present the case of 16-year-old woman with a 2-month history of ulcerative colitis who presented 
with cough, fever, dyspnea on exertion, and nasal congestion. Computed tomography of the chest 
demonstrated peripheral alveolar opacities with relative sparing of the central portions of the lungs. The 
clinical and radiologic findings raised the suspicion of eosinophilic pneumonia, possibly drug-related. 
The patient had recently been started on a trial of Mesalamine (5-aminosalicylic acid or 5-ASA) for 
treatment of her ulcerative colitis 2 months ago. The patient’s condition improved after discontinuation 
of mesalamine and treatment with prednisone. The clinical course and radiologic features supported the 
presumptive diagnosis of Mesalamine-induced eosinophilic pneumonia.
The patient is a 16 year-old female who was diagnosed 
with ulcerative colitis two months earlier. Prior to this di-
agnosis she had no significant medical history and denied 
having any allergies. The initial treatment of her ulcerative 
colitis included a trial of Mesalamine. Within a month 
after diagnosis, the patient presented to the emergency 
department complaining of a two-week history of cough, 
nasal congestion, dyspnea on exertion, sore throat, head-
ache, fever, chest and neck pain. Her work up included a 
lumbar puncture, chest x-ray, and Epstein-Barr virus titers, 
all of which were negative. As a result the patient was 
discharged home with non-specific diagnoses of head-
ache and dehydration. On present admission, the patient 
complains of worsening symptoms. Her review of systems 
was positive for a seven-pound weight loss, night sweats, 
and chills. Regarding her ulcerative colitis, she stated that 
she continued to have diarrhea and abdominal pain but 
these symptoms were improving. Her vitals on admission 
were: Temperature of 101.4 degrees Farenheit, heart rate 
of 86 beats per minute, respiratory rate of 20 breaths per 
minute, blood pressure of 112/75 mm Hg, height of 5 feet 
and 1/2 inches, and weight of 94 lbs. Physical examina-
tion was significant for decreased breath sounds bilaterally. 
Laboratory studies revealed an elevated white blood cell 
count with increased eosinophils and a microcytic anemia. 
Her sedimentation rate was elevated and she had a positive 
perinuclear staining anti-neutrophil cytoplasmic antibody 
(p-ANCA). Additional lab work was negative for: rheuma-
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Figure 1. 16-year-old woman with presumptive Mesalamine-induced eosinophilic pneumonia. PA and lateral chest images at 
presentation show bilateral peripheral areas of consolidation with an upper predominance. Slight prominence of the right hilum 
is apparent which represented lung disease within the medial portion of the right lung.
toid factor, angiotensin-1 converting enzyme (ACE), and 
human immunodeficiency virus (HIV).
Radiography of the chest showed bilateral, peripheral 
upper lobe opacities with air bronchograms and possible 
adenopathy (Fig. 1). CT of the chest was obtained for 
further evaluation of the peripheral lung parenchymal 
process seen on chest X-ray (Fig. 2). The chest CT also 
demonstrated extensive peripheral alveolar opacities in the 
mid and upper lungs bilaterally which were fairly sym-
metrical with relative sparing of the central portion of both 
lungs and the lung bases. There was no significant hilar 
adenopathy. Based on the patient’s symptomatic presenta-
Figure 2.  At time of presentation, axial contrast enhanced chest CT at the level just below the carina shows bilateral peripherally 
located areas of consolidation with air-bronchograms. The more central lung areas are free of the process.
Eosinophilic Pneumonia in a Patient with Ulcerative Colitis
RCR Radiology Case Reports | radiology.casereports.net 3 DOI: 10.2484/rcr.2007.v2i4.49
Figure 3. A, At time of presentation, 2D coronal reconstruction of the contrast-enhanced chest CT emphasizes the peripheral 
location of the lung opacities. B Nine days after discontinuation of mesalamine and onset of steroid therapy, 2D coronal recon-
struction chest CT shows marked improvement.
tion, laboratory findings, and her radiographic pattern 
of peripheral parenchymal consolidation, the patient was 
diagnosed with eosinophilic pneumonia.
The patient was taken off Mesalamine due to sus-
pected Mesalamine-induced eosinophilic pneumonia 
and started on prednisone plus 6-mercaptopurine for her 
ulcerative colitis. In less than a week the patient showed 
significant symptomatic improvement with correspond-
ing improvement of chest X-ray and CT scan. Given the 
fairly rapid improvement of these peripheral opacities, an 
eosinophilic-related process was felt to be most likely. In 8 
days, her white blood cell count started to normalize and 
the eosinophilia had resolved. The patient was discharged 
home in stable condition.
Discussion
Mesalamine (5-aminosalicylic acid or 5-ASA) is widely 
used as the maintenance therapy for ulcerative colitis. 
Although very rare, Mesalamine-induced pulmonary 
toxicity has been documented in the literature [1-9], with 
eosinophilic pneumonia as the most common presentation 
[2]. Clinical manifestations can occur anywhere from 2 to 
6 months after initiating Mesalamine treatment. Patients 
commonly present with dyspnea on exertion, fever, chest 
pain, and cough [2, 3, 4]. Patients’ laboratory findings may 
include eosinophilia and a positive perinuclear staining 
anti-neutrophilic cytoplasmic antibody (positive p-ANCA 
typically found in patients with ulcerative colitis) [2, 5]. 
The sedimentation rate was elevated in our case, but it 
can be normal [3]. Radiographic findings of Mesalamine-
induced lung toxicity are reported to be nonspecific with 
findings that include interstitial opacities, peripheral or 
diffuse acinar infiltrates, and pleural effusions [3,4 ]. Our 
patient exhibited mainly peripheral lung opacities with-
out a pleural effusion. Prompt resolution of lung disease 
after cessation of mesalamine, with or without steroids is 
the usual course [1, 3, 4, 6-8]. The rapid improvement in 
clinical and radiographic findings in the above patient after 
the discontinuation of Mesalamine strongly supports the 
diagnosis of mesalamine-induced eosinophilic pneumonia 
[1, 6, 8].
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